By Elias Schisgall
Shares of Paysign surged after the company posted higher revenue in the fourth quarter and issued an upbeat outlook for 2026 ahead of analyst expectations.
Shares were up 34% to $5.04 as of late Wednesday morning. The stock has doubled in value over the past year.
The company, which provides financial services for the life sciences industries, on Tuesday reported a fourth-quarter profit of $1.4 million, or two cents a share, roughly unchanged from its profit a year earlier, and in line with the expectations of analysts polled by FactSet.
Revenue rose to $22.8 million, from $15.6 million a year prior. Analysts were expecting revenue of $21.5 million, according to FactSet.
Revenue from the pharmaceutical industry more than doubled to $9.6 million, from $4.3 million a year earlier. Plasma industry revenue rose to $12.6 million from $10.8 million.
For the current first quarter, the company is projecting revenue between $27 million and $27.5 million, representing growth between roughly 45% and 48%. Earnings are projected between seven cents and eight cents a share.
Analysts are expecting first-quarter revenue of $24.4 million and five cents a share in earnings.
The company is expecting full-year revenue between $106.5 million and $110.5 million, with earnings between 21 cents and 26 cents a share.
Analysts are expecting full-year revenue of $99.1 million with earnings of 19 cents a share.
Plasma revenue is expected to be lowest in the first quarter, as the receipt of tax refunds reduces plasma donation frequency, before ramping up through the year.
Revenue from the pharmaceutical industry is expected to be highest in the first quarter, before ramping down throughout the year alongside patient affordability claims.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
March 25, 2026 11:18 ET (15:18 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments